PTGS2 and colorectal carcinoma: Previous studies highlight the clinical potential of selective COX-2 inhibitor celecoxib (CXB) in CRC treatment, demonstrating anti-inflammatory, analgesic effects and enhanced antitumor immunity of CXB [28,29].